Genus PLC
16 November 2006


For Immediate Release                                          16 November 2006


                                   Genus plc


                                 Result of AGM

                       Move from AIM to the Official List

                               Board Appointment

Genus plc ('Genus') is pleased to announce that at its Annual General Meeting 
held today, all resolutions were passed.

The resolutions included shareholder approval to the Company's proposed move from 
AIM to the Official List. It is intended that the move will take place at a time 
after the announcement in March 2007 of Genus' interim results statement for the 
six month period ended 31 December 2006 which will be prepared in accordance with 
IFRS.

Genus is also pleased to announce the appointment of Professor Barry Furr, OBE,
as a non-executive director with effect from 1st December 2006.

Professor Furr, aged 62, recently retired as Chief Scientist and Head of Project
Evaluation for AstraZeneca plc after 34 years of service. He was awarded an OBE
in 2000 for his services to cancer drug discovery and was the inventor of
Zoladex, a world leading anti-cancer drug.

John Hawkins, Chairman of Genus, said:

'Genus currently invests in excess of £12m per annum in research and
development. In addition to his duties on the Board, Professor Furr will chair a
Genus R&D Steering Group, comprising leading scientists in biotechnology and
animal genetics from around the world, which has the over-riding objective of
achieving early commercial breakthroughs for Genus. The Board believes Professor
Furr's substantial knowledge and experience in bioscience will contribute
significantly to the future success of Genus.'

The following is disclosed in accordance with Schedule 2 of the AIM Rules:

Current Directorships                  Directorships in the last 5 years
The Biosciences Federation             Biscientifica Ltd
Cancer Research UK                     AstraZeneca India Private Ltd
Breast Cancer Campaign
Manchester Technology Fund Ltd
Academy of Medical Sciences
Avesthagan Ltd India


There are no other matters under paragraph (g) of Schedule 2 of the AIM rules to
be disclosed.

For further information please contact:

Genus plc                                           Tel: 01256 347 100
Richard Wood, Chief Executive
David Timmins, Finance Director

Buchanan Communications                             Tel: 020 7466 5000
Charles Ryland
Suzanne Brocks
Simon Potter



                      This information is provided by RNS
            The company news service from the London Stock Exchange